Cart
sales@molnova.com
NVP-BHG712
CAS No. 940310-85-0
NVP-BHG712( NVP BHG712 | NVP BHG-712 | NVP BHG 712 | BHG-712 | BHG712 )
Catalog No. M16727 CAS No. 940310-85-0
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 201 | In Stock |
|
| 50MG | 372 | In Stock |
|
| 100MG | 556 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNVP-BHG712
-
NoteResearch use only, not for human use.
-
Brief DescriptionNVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition.
-
DescriptionNVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
-
In Vitro——
-
In VivoAnimal Model:Mice arrying chambers.Dosage:3, 10 and 30 mg/kg.Administration:P.O. daily for 4 days.Result:Significantly inhibited VEGF stimulated tissue formation and vascularization at doses of daily 3 mg/kg. Administration of 10 mg/kg/kg p.o. was sufficient to reverse VEGF enhanced tissue formation and vessel growth.
-
SynonymsNVP BHG712 | NVP BHG-712 | NVP BHG 712 | BHG-712 | BHG712
-
PathwayTyrosine Kinase
-
TargetEphrin Receptor
-
RecptorEphB4
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number940310-85-0
-
Formula Weight503.489
-
Molecular FormulaC26H20F3N7O
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NC1=CC=CC(C(F)(F)F)=C1)C2=CC=C(C)C(NC3=C4C(N(C)N=C4)=NC(C5=CC=CN=C5)=N3)=C2
-
Chemical Name4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Martiny-Baron G, et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 2010 Sep;13(3):259-67.
molnova catalog
related products
-
DY-131
DY131 is a novel selective agonist of ERRβ and ERRγ.
-
KYL
EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. Exhibits a long half life in cell culture media (8 and 12 hours in PC3 and C2C12 media respectively). Neuroprotective.
-
UniPR505
UniPR505 is a potent EphA2 antagonist (IC50: 0.95 μM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.
